Loading...
Direct oral anticoagulants (DOACs) have advantages over warfarin, including the lack of need for monitoring, a lower rate of major bleeding, absence of dietary vitamin K interaction, a shorter half-life, and lack of need for bridging with other agents around the time of procedures. Previously, some physicians and patients were reluctant to use DOACs because of the unavailability of an antidote. However, idarucizumab has recently been approved as a reversal agent for the DOAC dabigatran, and andexanet alfa has been approved as a reversal agent for the DOACs rivaroxaban and apixaban. Now, members of the Anticoagulation Forum have provided indications for proper use of these reversing…